Strategy and objectives
Immunovia’s strategy is to discover, develop and establish more accurate and reliable tools for the early diagnosis of cancers and autoimmune disorders for more effective treatment, based on the IMMray™ platform and approach – ensuring that we continuously deliver clinically useful and economically viable tools that improve healthcare worldwide.
We will accomplish this by extracting maximum value from the IMMray™ platform through developing, validating and commercializing diagnostic new tests for unmet clinical needs in cancer and autoimmunity, focusing on the early detection, disease monitoring and patient response to treatment where the clinical benefit for patients and healthcare is particularly high, existing solutions are lacking or insufficient, and IMMray™ has its main competitive advantages. Our first test in the commercialization phase is IMMray™ PanCan-d, a test for the early diagnosis of pancreatic cancer in high risk groups, that has the potential to significantly improve survival rates.
Immunovia’s goal is to provide more accurate and reliable tools for the early diagnosis of several cancers and autoimmune disorders based on the IMMray™ platform, establishing them as standards in healthcare worldwide.
Our ambition is that Immunovia’s tests will be the first choice for specialist physicians and general practitioners, used globally for testing of risk groups.
Lastly, the most important objective for us is to provide answers for the patients and their families, answers that will improve their lives.